After obtaining an MPharm (Hons) degree from the University of Nottingham in 2003, I spent fourteen months working as a community pharmacist/district manager with Alliance Pharmacy and remain a registered pharamacist with the General Pharmaceutical Council (GPhC).
I obtained my PhD from the University of Nottingham 2009, under the supervision of Prof. Barrie Kellam and Prof. Stephen Hill. The work from my PhD formed the basis for a Wellcome Trust Seeding Drug Discovery project focusing on the lead optimisation of new highly selective beta-blockers, which I continued to work on for three years as a post-doctoral research fellow.
I subsequently spent two and a half years as a senior research fellow with Prof. Peter Scammells at the Monash Institute of Pharmaceutical Sciences (Melbourne, Australia) working on a variety of projects.
I returned to Nottingham in 2014, after appointment as an Assistant Professor in Medicinal Chemistry, within the School of Pharmacy. In addition to my research interests, I am Course Director for Postgraduate-Taught programmes offered by the school.
Undergraduate - MPharm:
B33RPJ (Research Project)
B34ADD (Advanced Drug Discovery)
Postgraduate - MSc Drug Discovery and Pharmaceutical Sciences:
B34FDD (Fundamentals of Drug Discovery)
B34DD1 (Drug Discovery and Development 1)
B34RES (Research Project)
Module Convenership: B34FDD, B34RES
My group has an interest in the application of synthetic organic and medicinal chemistry. This involves the design, synthesis, purification and characterisation of small molecules and peptides in the… read more
FYFE, TJ, ZARZYCKA, B, LIM, HD, KELLAM, B, MISTRY, SN, KATRICH, V, SCAMMELLS, PJ, LANE, JR and CAPUANO, B, 2018. A Thieno[2,3-d]pyrimidine Scaffold is a Novel Negative Allosteric Modulator of the Dopamine D2 Receptor Journal of Medicinal Chemistry.
VAN DER WESTHUIZEN, ET, SPATHIS, A, KHAJEHALI, E, JORG, M, MISTRY, SN, CAPUANO, B, TOBIN, AB, SEXTON, PM, SCAMMELLS, PJ, VALANT, C and CHRISTOPOULOS, A, 2018. Assessment of the molecular mechanisms of action of novel 4-phenylpyridine-2-one and 6-phenylpyrimidin-4-one allosteric modulators at the M1 muscarinic acetylcholine receptor Molecular Pharmacology.
EMTAGE, ABIGAIL L., MISTRY, SHAILESH N., FISCHER, PETER M., KELLAM, BARRIE and LAUGHTON, CHARLES A., 2017. GPCRs through the keyhole: the role of protein flexibility in ligand binding to β-adrenoceptors. Journal of Biomolecular Structure & Dynamics. 35(12), 2604-2619
BAKER JG, GARDINER SM, WOOLARD J, FROMONT C, JADHAV GP, MISTRY SN, THOMPSON KS, KELLAM B, HILL SJ and FISCHER PM, 2017. Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease. FASEB Journal. 31(7), 3150-3166
My group has an interest in the application of synthetic organic and medicinal chemistry. This involves the design, synthesis, purification and characterisation of small molecules and peptides in the pursuit of novel drug discovery, or the development of tool compounds. In particular, we have a focus on developing allosteric, orthosteric and bitopic ligands for G Protein-coupled receptors (GPCRs) and other proteins to understand better how these proteins work. Current GPCR targets of interest are β-adrenoceptors, the M1 Muscarinic receptor, the D2 Dopamine receptor.
My previous work within the drug discovery team at Nottingham focused on the discovery and development of novel, highly selective beta-blockers. Taking compounds discovered during my PhD, we undertook an intensive lead-optimisation programme to develop a number of advanced leads with an improved selectivity profile and ADMET properties compared to existing beta blockers.
At Monash university, I was involved in the discovery and development of novel allosteric ligands for a number of G protein-coupled receptor (GPCR) targets, including:
- M1 muscarinic acetylcholine receptor
- D2 dopamine receptor
- Calcium-sensing receptor
Through collaboration, we combined our ligand-based approaches with structural and computational techniques, to gain insight into both the locality and mechanism of allosteric interaction at different GPCRs.
Other areas of research include the development of novel inhibitors, targeting multiple enzymes in the parasite Plasmodium falciparum, as a new strategy in the fight against malaria.